Drug recall · February 28, 2024
Norepinephrine Bitartrate in 5% Dextrose Injection recall
Why: Incorrect product concentration on the overwrap label: The overwrap label incorrectly identified the product strength as 4 mg / 250 mL; however, the primary bag label correctly identified the product strength as 8 mg / 250 mL.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Norepinephrine Bitartrate in 5% Dextrose Injection, 8 mg/ 250 mL (32 mcg/mL), For Intravenous Infusion Only, 250 mL vial, Rx Only, Baxter Healthcare Corporation, Deerfield, IL 60015. Made in Ireland. NDC: 0338-0108-20
- Lots / codes
Lot 23I21G64; Exp. 07/31/2024
- Quantity
- 13,000 bags
- Company
- Baxter Healthcare Corporation, Deerfield, IL
- Distribution
- Nationwide in the USA
- Initiated
- January 23, 2024 · Voluntary: Firm initiated
- Classified
- February 16, 2024
- Reported
- February 28, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Norepinephrine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.